The US Pharmaceutical Manufact-urers Association has filed suit against Arkansas' new Medicaid prior-authorization program, claiming it violates state laws and the 1990 federal Omnibus Budget Reconciliation Act.
Among the program's requirements is the need for prescribers of single-source non-steroidal anti-inflammatory drugs to include evidence that use of the product is for an approved indication. This violates the Act by placing restrictions on covered drugs, and could lead to the removal of federal funding.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze